Şunu aradınız:: oy to (Yunanca - İngilizce)

oy,
adartrel

abbott oy
uc

astrazeneca oy αίνα∆
oral use

algol pharma oy
algol pharma oy

vetcare oy, p. o.
vetcare oy, p. o.

oy leiras finland ab
oy leiras finland ab

suomi/ finland oy h.
suomi/ finland oy h.

frankfoýrth , 6 april oy 1998
frankfurt , 6 april 1998

suomi/ finland abbott oy
abbott oy

suomi/finland msd finland oy
suomi/finland msd finland oy puh/tel: +358 (0) 9 804650 info@msd. fi

astrazeneca oy luomanportti 3 02200 espoo
astrazeneca oy luomanportti 3 02200 espoo

abbott oy pihatörmä 1a/ gårdsbrinken 1b
suomi/finland abbott oy pihatörmä 1a/gårdsbrinken 1b

suomi/finland sanofi-aventis oy
suomi/finland sanofi-aventis oy puh/tel: +358 (0) 201 200 300

Υπόθεση 140/89 — neste oy/Επιτρο­πής
140/89 neste oy ν commission

bayer oy, bayer schering pharma bayer ab bayer plc
bayer ab bayer plc

helsinki, finland: hobby-kustannus oy, 1999.
helsinki, finland: hobby-kustannus oy, 1999.

to eni qevre thn antikatástash ayt problhmatik l gv toy gegon tow ti molon ti to eni qa teqe ntvw yp ekkaqárish me th sýstash thw ekt , h ekkaqárish ayt qa oloklhrvqe sthn arx toy tr toy stad oy .
the emi considers such a replacement to be problematical owing to the fact that , although it is true that the emi will go into liquidation on the establishment of the ecb , its liquidation shall be completed by the beginning of the third stage .

( ekt/ 1998/11)( 98/ c 411/07)( ypobl qhke ap thn eyrvpa k kentrik trápeza stiw 3 noembr oy 1998) to symboylio ths eyrvpa khs envshs,
( ecb/ 1998/11)( 98/ c 411/07)( submitted by the european central bank on 3 november 1998) the council of the european union,